Advertisements

Лотонел

Quick links to important sections

Лотонел

Selected form

Advertisements
Advertisements

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Лотонел

What is Лотонел: Definition and Classification

Property Description
Active ingredient Torasemide (INN)
Form Oral tablets, IV solution
Pharmacological class Loop Diuretic (High-ceiling)
General Purpose Managing excess fluid (edema)
Origin Synthetic compound

The medicine Лотонел is defined by its sole active chemical component, Torasemide (INN), a synthetic compound of the pyridine-sulfonylurea chemical class. It is formally classified as a potent loop diuretic, a category sometimes termed a high-ceiling diuretic due to its substantial ability to increase urine output. Torasemide exhibits high oral bioavailability.

Composition and Available Forms of Torasemide

This medication is manufactured as a single-ingredient product, containing only the active substance Torasemide. It is primarily supplied in two distinct pharmaceutical preparations: solid oral tablets and a sterile intravenous solution (IV form). The product is composed of Torasemide integrated into an inert tablet base for convenient oral use, or dissolved in an aqueous solution for direct administration via the Intravenous route. The availability of both forms supports therapeutic continuity, allowing patients to transition from acute hospital care to chronic management.

General Purpose of Лотонел (Torasemide)

The general therapeutic purpose of Torasemide is to assist the body in eliminating excessive volumes of fluid and salt. Its core action as a powerful loop diuretic leads to marked natriuresis (sodium excretion) and diuresis (water excretion), which results in the relief of fluid retention, a condition medically termed edema. The medication is also utilized for its anti-hypertensive properties. This reduction of surplus fluid contributes directly to the overall management of conditions where fluid overload is a concern, such as in patients with congestive heart failure.

Advertisements

What side effects are possible with Лотонел?

Possible Side Effects and Safety Information

The safety profile of Torasemide (Лотонел), a loop diuretic, is defined by its action on fluid and electrolyte balance, as documented in official regulatory sources. Adverse reactions are classified by frequency and grouped into System-Organ Classes.

Adverse Reaction Classification

The most commonly documented adverse reactions, classified as Common (ge 1/100 to < 1/10), relate to the drug’s primary effect and include disturbances in fluid and electrolyte balance (e.g., Hypokalemia, Hypovolemia), headache, dizziness, fatigue, and gastrointestinal disturbances (e.g., nausea, diarrhea).

Reactions classified as Uncommon (ge 1/1,000 to < 1/100) include paresthesia and increases in blood urea and creatinine concentrations.

Serious Safety Characteristics

Official labeling highlights the potential for serious adverse reactions, although they may be rare. These include ototoxicity (tinnitus and hearing loss), which may be increased at higher doses or in patients with severe renal impairment. In patients with severe hepatic impairment, Torasemide carries the risk of precipitating hepatic coma or encephalopathy, a major safety constraint.

Population-Specific Notes

Safety notes specify that older adults are at an increased risk of volume depletion, dehydration, and potential thromboembolic complications. Use is formally restricted in patients presenting with Anuria (absence of urine production) or pre-existing severe Hypokalemia until the deficiency is corrected. Symptoms of volume depletion, such as dizziness and hypotension, are typically more likely to occur at the start of treatment or following dose increases.

Advertisements

Overdose and Emergency Response

Overdosage of Лотонел (Torasemide) is formally documented in regulatory prescribing information as presenting with the consequences of an exaggerated diuretic effect, specifically profound volume depletion and hypotension. This state leads to critical electrolyte and acid-base disturbances, including hyponatremia and hypokalemia. Documented clinical signs may include severe dehydration, weakness, lethargy, confusion, and muscular cramps.

The regulatory documents cite potential life-threatening outcomes associated with this depletion, such as acute renal failure, the risk of thrombosis or embolism, and seizures. In patients with pre-existing hepatic disease, overdose may precipitate hepatic coma.

Due to the severity of these documented manifestations, official government guidance requires individuals to seek immediate medical help or contact a Poison Control Center immediately in the event of suspected overdosage. Management is officially described as symptomatic and supportive treatment, focusing on aggressive volume replacement and correction of electrolyte deficits. No specific antidote is available for Torasemide overdose. Hospital management includes mandated close monitoring of kidney function and serum electrolytes.

Advertisements

Therapeutic Uses of Лотонел

What Лотонел treats: main uses and benefits

Лотонел (Loteprednol) is commonly used in situations involving symptoms related to inflammatory or irritative states and is applied across domains where additional symptomatic support is needed.

The medication is utilized as part of symptomatic management for conditions characterized by periods of heightened symptoms. It is used for managing ocular redness, swelling, pain, discomfort, and intense itching associated with conditions like seasonal allergies and inflammation following eye procedures.

The medication is relevant in contexts marked by increased discomfort, and may assist with providing supportive relief when symptoms interfere with routine activities.

“This medication is applied across domains where additional symptomatic support is needed, contributing to easing the overall symptom load during periods of heightened symptoms.”

It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations when symptoms create noticeable interference with daily comfort, and contributes to easing the overall symptom load during symptomatic phases.


Quick Fact: Relief for Inflammation Symptoms Лотонел is relevant when short-term symptomatic assistance is needed to address visible symptoms like redness and swelling, as well as internal discomfort like pain and itching.

Regulatory References

  1. NIH MedlinePlus overview
Advertisements

Eligibility and Restrictions for Use

This information describes the official restrictions and contraindications for use of Loteprednol Etabonate (Лотонел), as stated in governmental regulatory documents.

Contraindicated Populations (Must Not Use)

The medicine is formally contraindicated and must not be used by individuals with the following active ocular infections:

  • Viral Diseases: Most viral infections of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella.
  • Mycobacterial Infection: Infections of the eye caused by mycobacteria.
  • Fungal Diseases: Fungal diseases affecting ocular structures.
  • Hypersensitivity: Known or suspected allergy to loteprednol etabonate or any of the product's ingredients.

Eligibility-Related Restrictions and Cautions

Category Regulatory Requirement
History of Infection Requires great caution in patients with a history of herpes simplex, due to the risk of worsening the infection.
Eye Conditions Should be used with caution in the presence of glaucoma or in diseases that cause thinning of the cornea or sclera, as topical steroids may increase intraocular pressure (IOP) or risk perforation.
Prolonged Use Use for 10 days or longer requires regular monitoring of intraocular pressure (IOP).
Age Restriction Not all formulations are approved for use in children; generally restricted to adults (age 18 and older) unless specifically indicated by the regulatory document.

For any pre-existing eye condition or current infection, a full examination by a healthcare professional is mandatory before starting or continuing this medication.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Лотонел (Torasemide) documents several clinically significant interaction patterns, primarily categorized as pharmacodynamic potentiation and pharmacokinetic alterations.

Pharmacodynamic Potentiation

Co-administration with Antihypertensive Agents, such as ACE inhibitors, can result in a potentiation of the blood pressure-lowering effect, increasing the risk of severe hypotension. Regulatory labeling mandates reducing or temporarily stopping the Torasemide dose 2 to 3 days prior to initiating treatment with an ACE inhibitor. Torasemide also increases the risk of ototoxicity and nephrotoxicity when taken with Aminoglycoside antibiotics or Cisplatin. The risk of cardiac glycoside toxicity (e.g., Digoxin) is increased due to Torasemide-induced hypokalaemia.

Pharmacokinetic Alterations

Torasemide is a substrate for CYP2C8 and CYP2C9 enzymes; co-administration with CYP2C9 inhibitors may decrease its clearance, potentially increasing systemic exposure. Torasemide also reduces the renal clearance of Lithium, leading to elevated serum concentrations and increased toxicity risk. Cholestyramine reduces the oral absorption of Torasemide, lowering its bioavailability. Conversely, co-administration with Digoxin is reported to increase Torasemide's exposure (AUC) by up to 50%. No specific interactions with food, alcohol, or herbal products are required to be listed in the formal drug interaction sections of major regulatory documents.

Advertisements

Mechanism of Action

Molecular Mechanism: Blockade of Renal Salt Transport

The drug's primary activity is focused on the kidney tubules, where it acts as a specific inhibitor of the Na^+/ K^+/ 2 Cl^- co-transporter ( NKCC2) in the thick ascending limb of the Loop of Henle. This molecular blockade prevents the reabsorption of salt and water, initiating the diuretic cascade.


Creation of an Osmotic Diuretic Gradient

By blocking the NKCC2 transporter, the drug ensures that a high concentration of sodium and chloride remains within the tubular fluid, generating an osmotic gradient. This gradient acts as a physical force, preventing water from being reabsorbed in distal parts of the kidney and leading to volume reduction and loss of total extracellular fluid.


Modulation of Systemic Fluid and Extra-Renal Pathways

Beyond its main renal action, the mechanism contributes to the modulation of overall Extracellular Fluid Volume, and may also involve extra-renal effects, including modulation of vascular smooth muscle tone and interference with profibrotic pathways associated with aldosterone. The full physiological activity of this mechanism, however, is constrained by renal function and the potential for the kidney's own compensatory salt-reabsorption processes (braking phenomenon) to constrain the diuretic mechanism over time.

Advertisements

Dosage and Administration Information

The administration of Лотонел (Torasemide) is based on established parameters concerning the route, frequency, and dose adjustment rules for different conditions.

Routes and Administration Timing

Torasemide is used via Oral Tablets and, in some settings, as an Intravenous (IV) Solution for acute needs. The tablets are taken once daily, typically in the morning, and may be administered with or without food as the overall bioavailability is not significantly altered.

Standard Dosing and Adjustment Rules

Dosing is based on the condition being addressed, with quantities stated in milligrams (mg):

Condition Initial Dose (Oral, once daily) Maximum Studied Dose
Edema (Heart/Renal Disease) 10 mg or 20 mg 200 mg
Edema (Hepatic Cirrhosis) 5 mg or 10 mg 40 mg
Hypertension 5 mg 10 mg

For edema, the dose is increased by doubling the current dose if the response is inadequate, staying within the maximum studied limits. For hypertension, the initial 5 mg dose can be increased to 10 mg after four to six weeks if the blood pressure reduction is insufficient.

Special Procedural Requirements

When managing edema associated with hepatic cirrhosis, Torasemide is administered together with an aldosterone antagonist or a potassium-sparing diuretic. For a missed dose, the dose is taken as soon as remembered; however, a dose is skipped if it is near the time for the next scheduled dose to avoid doubling.

Special Populations: Clinical parameters indicate no special dosage adjustments are necessary for older adults. However, higher oral doses may be required for individuals with renal impairment to achieve the desired effect.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Лотонел (Loteprednol)

Evidence for Use in Managing Post-Operative Ocular Inflammation

The research utilized randomized, controlled trials (RCTs) to evaluate Loteprednol (an ophthalmic corticosteroid), often comparing it to an inactive vehicle (placebo) drop. Research primarily examined outcomes related to physical discomfort and inflammatory states in adult patients after uncomplicated procedures, such as cataract surgery.

Studies were structured to measure outcomes including the proportion of patients where complete resolution of anterior chamber inflammation was measured (a cell score of zero) and the proportion of patients reporting no ocular pain during the short-term assessment period. The resulting data describe patterns observed in these key short-term measurements when compared to the vehicle drop. This body of evidence contributes to the broader evidence landscape used by regulators to assess the study patterns for this specific post-operative setting.

Long-term outcomes are not well characterized by the core evidence base. The primary endpoints were typically measured within the first two weeks, and follow-up durations were limited.


Evidence for Use in Specific Steroid-Responsive Inflammatory Conditions

Loteprednol was studied in conditions involving periods of heightened symptoms, such as seasonal allergic conjunctivitis and giant papillary conjunctivitis (GPC). Research in this area also utilized randomized, vehicle-controlled trials that focused on assessing outcomes linked to inflammatory or irritative states.

Researchers relied on patient-reported outcomes describing perceived discomfort, including scores for ocular itching and redness during periods of increased symptom activity, and also monitored the measurement of objective clinical signs. This evidence helps contextualize how patients reported their experience of temporary symptomatic changes.

Evidence is specific to the inflammatory types studied. Since these conditions may be recurring, the limited information for long-term outcomes or strategies for conditions presenting with cycles of stability and flare-ups means the research focuses primarily on the acute, short-term episode.


What Remains Undefined or Uncertain in the Research

The research highlights several areas where certainty remains low or where additional data would contribute to a clearer picture. Comparative evidence is lacking for large-scale, direct comparisons against all other major topical steroid drops. Furthermore, data for certain groups remain insufficient. For instance, while some pediatric patients and older adults were included, the sample sizes were modest for many specific populations, meaning that findings describe group patterns, not personal outcomes.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Лотонел (FAQ)


Q: How quickly should I feel the effect of Лотонел?

A: According to official product information, the diuretic (urine-increasing) effect of the oral tablet typically begins within 1 hour of administration. The maximum effect usually occurs during the first or second hour. The primary diuretic effect is described as lasting approximately 6 to 8 hours in clinical data.


Q: How long can a person safely be on Лотонел?

A: The maximum safe duration of use is not specified in regulatory documents, as it depends on the patient's chronic condition. Clinical trials supporting the drug's approval involved subjects who continued treatment for over 1 year. The duration of use should be determined based on the patient's individual condition and ongoing monitoring.


Q: Does Лотонел cause weight gain or loss?

A: The drug's primary action is to increase the excretion of excess water and salt from the body. While official labeling does not list weight loss as a specific adverse reaction, the resulting reduction in fluid volume is associated with a decrease in body weight.


Q: Can Лотонел affect my mood or sleep?

A: Insomnia (difficulty sleeping) and nervousness have been reported as adverse events. These are noted in official reports concerning the drug’s potential effect on the central nervous system. Mood changes have also been reported, though less frequently.


Q: Why do doctors prescribe Лотонел for this specific issue?

A: It is officially indicated for managing fluid retention (edema) in patients with heart failure, kidney disease, or liver disease. It is also approved to treat high blood pressure (hypertension) due to its strong ability to reduce the body’s total fluid volume.


Q: Is it possible to develop a tolerance to Лотонел over time?

A: Official information notes that with chronic administration, the body's natural processes cause daily sodium loss to eventually balance with dietary intake. This compensatory process may influence the diuretic response over time, which is sometimes referred to as the braking phenomenon.


Q: What is the maximum amount of time before a dose is considered 'too late' to take?

A: If a dose is missed, it should be taken as soon as remembered. However, the dose must be skipped entirely if it is near the time for the next scheduled dose. Regulatory information does not define the exact number of hours considered 'near' the next dose.


Q: Do I need to stop taking Лотонел gradually, or can I stop suddenly?

A: Official regulatory warnings caution against suddenly discontinuing the medication without consulting a healthcare professional. Abrupt discontinuation can potentially lead to an unwanted increase in blood pressure.


Q: What ingredients are in the Лотонел tablet?

A: The tablet is a single-ingredient product, containing only the active substance, Torasemide. This active substance is combined with an inert base. The full list of inactive ingredients, which forms the tablet base, is detailed in the official package insert.


Q: What are the less common, but serious, side effects of Лотонел?

A: Official warnings highlight several serious risks, including ototoxicity (hearing issues like ringing or loss), the potential for precipitating hepatic coma in patients with severe liver impairment, and development of acute kidney issues. Professional medical attention is advised if symptoms of a serious adverse event occur.


Q: Can teenagers or young adults use Лотонел?

A: Safety and effectiveness in pediatric patients have not been established in the official labeling. The drug is primarily intended for use in adults (age 18 and older) as safety and effectiveness have not been established in pediatric patients.


Q: What happens if I take two doses of Лотонел too close together?

A: Taking two doses too closely may result in symptoms related to overdose or excessive diuresis (excessive fluid loss). Signs can include changes in vision, confusion, or a drastic reduction in urine output. If these symptoms occur, seeking professional medical attention is appropriate.


Q: Does Лотонел interact with common stomach acid reducers?

A: The official label specifically notes an interaction with Cholestyramine, which can reduce the drug's absorption. While other common over-the-counter acid reducers are not individually listed, any medication that alters absorption could potentially affect the drug’s activity.


Q: What kind of relief can I realistically expect from Лотонел?

A: When used to manage high blood pressure, the anti-hypertensive effect is generally achieved after 4 to 6 weeks of consistent treatment. For fluid retention, the expected outcome is the elimination of excess fluid and a reduction in associated symptoms like swelling.


Q: Are there any long-term side effects associated with Лотонел use?

A: With long-term use, official warnings indicate the need for periodic monitoring of certain levels in the blood. This includes checking serum electrolytes and blood glucose levels, as the drug can potentially lead to imbalances like low potassium or high blood sugar.


Q: Is it normal to feel a bit dizzy after starting Лотонел?

A: Feelings of dizziness, lightheadedness, and other signs of volume depletion are noted in regulatory documents as being more likely to occur at the start of treatment or following a dose increase. This is a common effect related to the reduction of blood pressure and fluid.


Q: Does alcohol completely have to be avoided with Лотонел?

A: The use of alcohol can increase the risk of low blood pressure and dizziness when combined with this medication. Patients are generally advised to discuss alcohol consumption with their healthcare provider.


Q: Are there any known interactions between Лотонел and herbal supplements?

A: Official drug labels are not typically required to list interactions with specific herbal products. However, caution is generally advised with any herbal product that may affect the specific liver enzymes (CYP2C9) through which Лотонел (Torasemide) is metabolized.


Q: Is there a possibility of a headache when starting Лотонел?

A: Headache is classified as a Common side effect in official documents, meaning it was reported in 1% to 10% of patients in some studies. As a common effect, it can potentially occur when treatment is initiated.


Q: Is there a special way to store Лотонел tablets or liquid?

A: The tablets must be stored at Controlled Room Temperature (20 C to 25 C / 68 F to 77 F) and protected from light and moisture. The intravenous (liquid) solution has specific stability requirements for its diluted forms that are handled in a clinical setting.


Q: What are the signs of an allergic reaction to Лотонел?

A: The medication is contraindicated in individuals with known hypersensitivity. Symptoms of a severe allergic reaction can include hives, difficulty breathing, or swelling of the face, throat, or tongue. If these signs appear, seeking immediate medical attention is necessary.


Q: Is it important to take Лотонел at the exact same time every day?

A: The drug is prescribed to be taken once daily to maintain consistent therapeutic control. Taking it at a regular time each day helps ensure that the diuretic and anti-hypertensive effect is maintained throughout the full 24-hour cycle.


Q: How does pregnancy affect the decision to use Лотонел?

A: Official regulatory information states there are no available human data to inform the risk of major birth defects or miscarriage. The decision to use this medication during pregnancy requires a careful professional assessment that weighs the potential benefits against any possible risks, consistent with standard medical practice.

Advertisements

How should Лотонел be stored and disposed of?

Storage and Disposal Instructions for Torasemide

Torasemide (Lotoenel) tablets and injection must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), with temporary excursions permitted between 15 C and 30 C. The product must be protected from freezing, moisture, and direct light to maintain its stability. Tablets should be kept in a closed container.

Handling and Child Safety

The medication must be stored out of the reach of children. For the intravenous solution, diluted preparations are typically stable for 24 hours at room temperature.

Disposal

Unused or expired Torasemide must be discarded properly. Do not keep old medicine. Consult your healthcare professional or pharmacist for specific instructions on how to properly dispose of the unused product according to local guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Лотонел found in:

A-Z Index: